Press Releases

Date	Title
04/23/18	Akorn Asks Delaware Court to Require Fresenius Kabi to Fulfill Its Obligations under Merger Agreement LAKE FOREST, Ill. --(BUSINESS WIRE)--Apr. 23, 2018-- Akorn, Inc. (NASDAQ:AKRX), today filed a complaint in Delaware Chancery Court asking that Fresenius Kabi AG be required to fulfill its obligations under the definitive merger agreement, and issued the following statement: “Fresenius’ attempt to
04/22/18	Akorn Issues Statement LAKE FOREST, Ill. --(BUSINESS WIRE)--Apr. 22, 2018-- Akorn, Inc. (NASDAQ:AKRX), today issued a statement in response to Fresenius Kabi’s announcement that it is seeking to terminate the definitive merger agreement announced on April 24, 2017 . “We categorically disagree with Fresenius’ accusations.
02/26/18	Akorn Issues Statement on Investigation LAKE FOREST, Ill. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today issued the following statement: “Akorn and Fresenius Kabi AG, with the assistance of outside consultants, are investigating alleged breaches of FDA data

Keyword Search